Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-10-18
2011-10-11
Harris, Alana M (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007100, C435S007200, C435S007210, C436S501000, C436S503000, C436S063000, C436S064000
Reexamination Certificate
active
08034578
ABSTRACT:
The present invention provides the method of predicting an non-small cell lung cancer (NSCLC) prognosis.
REFERENCES:
patent: 2006/0024692 (2006-02-01), Nakamura et al.
patent: WO 00/66619 (2000-11-01), None
patent: WO02/086443 (2002-10-01), None
patent: WO 2004/031413 (2004-04-01), None
patent: WO 2005/089735 (2005-09-01), None
Aigner, K., et al. FEBS Letters, 851: 1617-1624, 2007.
Kundu, S. T., et al. Int. J. Cancer, 123: 2303-2314, 2008.
Heighway J, Betticher DC. Lung: Non-small cell carcinoma. Atlas Genet and Cytogenet Oncology Haematol, Feb. 2004.
Bonné, S., et al., “Plakophilin-3, a novel Armadillo-like protein present in nuclei and desmosomes of epithelial cells,” Jul. 1999,J. Cell Sci., vol. 112, pp. 2265-2276.
Bonné, S., et al., “Defining desmosomal plakophilin-3 interactions,” Apr. 2003,J. Cell Biol., vol. 161, pp. 403-416.
Callagy, G., et al., “Molecular classification of breast carcinomas using tissue microarrays,” Mar. 2003,Diagn. Mol. Pathol., vol. 12, pp. 27-34.
Chin, S.F., et al., “A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples,” Oct. 2003,Mol. Pathol., vol. 56, pp. 275-279.
Cojocaru, G., et al., “Transcriptional profiling of non-small cell lung cancer using oligonucleotide microarrays,” Mar. 2002,Chest, vol. 121, 44S.
Fujii, T., et al., “A preliminary transcriptome map of non-small cell lung cancer,”Jun. 2002,Cancer Res., vol. 62, pp. 3340-3346.
Furukawa, C., et al., “Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer,” Aug. 2005,Cancer Res., vol. 65, pp. 7102-7110.
Heighway, J., et al., “Expression profiling of primary non-small cell lung cancer for target identification,” Oct. 2002,Oncogene, vol. 21, pp. 7749-7763.
Kikuchi, T., et al., “Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs,” Apr. 2003,Oncogene, vol. 22, pp. 2192-2205.
Kononen, J., et al., “Tissue microarrays for high-throughput molecular profiling of tumor specimens,” Jul. 1998,Nat. Med., vol. 4, 844-847.
Papagerakis, S., et al., “Immunohistochemical localization of plakophilins (PKP1, PKP2, PKP3, and p0071) in primary oropharyngeal tumors: correlation with clinical parameters,” Jun. 2003,Human Pathol., vol. 34, pp. 565-572.
Sauter, G., et al., “Tissue microarrays in drug discovery,” Dec. 2003,Nat. Rev. Drug Discov., vol. 2, pp. 962-972.
Schmidt, A., et al., “Plakophilin-3—a novel cell-type-specific desmosomal plaque protein,” Jun. 1999,Differentiation, vol. 64, pp. 292-306.
Wang, T., et al., “Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis,” Mar. 2000,Oncogene, vol. 19, pp. 1519-1528.
Wigle, D., et al., “Molecular profiling of non-small cell lung cancer and correlation with disease-free survival,” Jun. 2002,Cancer Res., vol. 62, pp. 3005-3008.
Cheng, G., et al., “Protein profiles associated with survival in lung adenocarcinoma,”Proc Natl Acad Sci USA, vol. 100(23), pp. 13537-13542 (Nov. 11, 2003, Epub Oct. 22, 2003).
Sasaki, H., et al., “The investigation of gene analysis for development and metastasis in lung adenocarcinoma—using LightCycler,”The Journal of the Japanese Association for Chest Surgery, vol. 18(3), p. 200, Abstract P-135 (2004).
Daigo Yataro
Nakamura Yusuke
Nakatsuru Shuichi
Harris Alana M
Holleran Anne
Kilpatrick Townsend & Stockton LLP
Oncotherapy Science, Inc.
LandOfFree
PKP3 oncogene as a prognostic indicator for lung cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PKP3 oncogene as a prognostic indicator for lung cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PKP3 oncogene as a prognostic indicator for lung cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4264327